Active substanceCeftriaxoneCeftriaxone
Similar drugsTo uncover
  • Azaran
    powdersolution w / m in / in 
    Hemofarm AD     Serbia
  • Axon
    powder w / m in / in 
  • Betasporin
    powdersolution w / m in / in 
    Laboratorios Atral SA     Portugal
  • Biotrakson
    powdersolution w / m in / in 
  • Broadssef-S
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • IFICEF®
    powder w / m in / in 
  • Lendacin®
    powder d / infusion 
    Lek dd     Slovenia
  • Lifaxon
    powdersolution w / m in / in 
    FARMGID CJSC     Russia
  • Medaxon
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movigip®
    powder w / m in / in 
  • Oframax®
    powdersolution w / m in / in 
  • Rocefin®
    powder w / m 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder in / in 
  • Rocefin®
    powder w / m in / in 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
  • Steritsef®
    powdersolution for injections 
  • Tertsef®
    powdersolution w / m in / in 
    Aktavis, AO     Iceland
  • TOROCEF®
    powdersolution w / m in / in 
  • Triacson
    powdersolution w / m in / in 
  • Chizon
    powdersolution w / m in / in 
    Shin Pung Pharmaceutical Co., Ltd.     The Republic of Korea
  • Cefaxon
    powdersolution w / m in / in 
    Lupine Co., Ltd.     India
  • Cefatrine
    powdersolution w / m in / in 
  • Cefogram®
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriaxone
    powdersolution d / infusion 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Ceftriaxone
    powdersolution w / m in / in 
    RUZFARMA, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    RAFARMA, CJSC     Russia
  • Ceftriaxone
    powdersolution
    Mapichem AG     Switzerland
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    Vertex Exports     India
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOCHEMIST, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution
    SYNTHESIS, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    MAKIZ-PHARMA, LLC     Russia
  • Ceftriaxone
    powder w / m in / in 
    HIMFARM, JSC     Kazakhstan
  • Ceftriaxone
    powder w / m in / in 
  • Ceftriaxone Danson
    powdersolution w / m in / in 
  • Ceftriaxone DS
    powdersolution
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Protek
    powdersolution w / m in / in 
  • Elf Ceftriaxone
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Ceftriaxone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Ceftriaxone-Jodhas
    powdersolution w / m in / in 
  • Ceftriaxone-CmP
    powdersolution w / m in / in 
  • Ceftriaxone-LEXMM®
    powdersolution w / m in / in 
  • Dosage form: & nbspPowder for the preparation of solution for intravenous and intramuscular injection.
    Composition:
    each vial contains:

    active ingredient: ceftriaxone sodium (in terms of ceftriaxone) 1000 mg.
    Description:White or white with a yellowish tint powder.
    Pharmacotherapeutic group:Antibiotic-cephalosporin.
    ATX: & nbsp

    J.01.D.D.04   Ceftriaxone

    Pharmacodynamics:

    Ceftriaxone is a third generation cephalosporin antibiotic for parenteral use, has a bactericidal effect, inhibits the synthesis of the cell membrane, in vitro suppresses the growth of many gram-positive and gram-negative microorganisms. Ceftriaxone is resistant to the action of beta-lactamase enzymes (both penicillinase and cephalosporinase). In vitro and in conditions of clinical practice ceftriaxone is usually effective against the following microorganisms:

    Gram-positive:

    Coagulase-negative staphylococci (including Staphylococcus epidermidis), Staphylococcus aureus, (methicillin-sensitive strains), Streptococcus pneumoniae, Streptococcus groups A (Streptococcus pyogenes), Streptococcus group B (Streptococcus agalactiae), Streptococcus viridans.

    Note: Staphylococcus spp., resistant to methicillin, is resistant to cephalosporins, including ceftriaxone. Most strains of enterococci (for example, Streptococcus faecalis) also resistant to ceftriaxone.

    Gram-negative:

    Aeromonas spp., Alcaligenes spp., Moraxella catarrhalis, Citrobacter spp., Enterobacter spp. (some strains are stable), Escherichia coli, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella spp. (at Tom number of Klebsiella pneumoniae, Klebsiella oxytoca), Morganella morganii, Neisseria gonorrhoeae (including strains, resistant to penicillin), Neisseria meningitidis, Plesiomonas shigelloides, Proteus mirabilis, Proteus vulgaris, Providencia spp., Pseudomonas aeruginosa (many strains are stable), Salmonella spp. (at Tom number of Salmonella typhimurium), Serratia spp. (at Tom number of Serratia marcescens), Shigella spp., Vibrio spp. (at Tom number of Vibrio cholerae), Yersinia spp. (at Tom number of Yersinia enterocolitica)

    Note: many strains of these microorganisms, which in the presence of other antibiotics, for example, penicillins, first-generation cephalosporins and aminoglycosides, are multiplying steadily, are sensitive to ceftriaxone. Treponema pallidum is sensitive to ceftriaxone as in vitro, and in vivo. According to clinical data, in the primary and secondary syphilis, a good efficacy of ceftriaxone is noted. To ceftriaxone are resistant: Listeria monocytogenes, Mycoplasma spp., Stenotrophomonas maltophilia, Ureaplasma urealyticum.

    Anaerobic pathogens:

    Bacteroides spp. (including some strains Bacteroides fragilis), Clostridium spp. (at Tom number of Clostridium difficile), Fusobacterium spp. (Besides Fusobacterium mostiferum. Fusobacterium varium), Peptococcus spp., Peptostreptococcus spp.

    Note: Some strains of many Bacteroides spp. (eg, Bacteroides fragilis), Developing beta-lactamase, resistant to ceftriaxone. To ceftriaxone also exhibits resistance Chlamydia spp. To determine the sensitivity of microorganisms, discs containing ceftriaxone, since it is shown that in vitro to classical cephalosporins, certain strains of pathogens can be stable.

    Pharmacokinetics:

    Suction

    With intramuscular injection ceftriaxone is well absorbed from the site of administration and reaches high concentrations in the serum. Bioavailability of the drug is 100%.

    Time to reach the maximum concentration with intramuscular injection is 2 hours, with intravenous - at the end of infusion. With intramuscular injection, 1000 mg maximum concentration (CmOh) of ceftriaxone is 76 μg / ml. When administered intravenously at doses of 1000 or 2000 mg CmOh is 151 and 257 μg / ml, respectively.

    Distribution

    Ceftriaxone reversibly binds to albumin and this binding is inversely proportional to the concentration: for example,at a drug concentration in the serum of less than 100 mg / l, ceftriaxone binding to proteins is 95%, and at a concentration of 300 mg / l, only 85%. Due to the lower concentration of albumin in the tissue fluid, the percentage of free ceftriaxone in it is higher than in plasma. With parenteral administration ceftriaxone well penetrates into tissues and body fluids. Apparent volume of distribution is 5.78 - 13.5 liters. With intravenous administration ceftriaxone quickly diffuses into the interstitial fluid, where its bactericidal action against pathogens sensitive to it persists for 24 hours. Ceftriaxone concentrations exceeding the minimum inhibitory concentrations for most pathogens in tissues and body fluids (lungs, heart, bile ducts, liver, tonsils, middle ear and nasal mucosa, bones, as well as spinal, pleural and synovial fluids and secretion of the prostate ). Ceftriaxone passes through the placental barrier and penetrates into breast milk in small concentrations.

    Excretion

    The half-life in adults is about 8 hours, in elderly people over 75 years - increases 2 - 3 times, in newborns - up to 8 days. Ceftriaxone is deduced, basically, in an invariable kind by kidneys (50 - 60% from the entered dose). 40-50% is also excreted in unchanged form with bile. In newborns, about 70% of the dose administered is excreted by the kidneys. The total plasma clearance of ceftriaxone is 10-22 ml / min. Kidney clearance is 5-12 ml / min. With moderate renal insufficiency or liver pathology in adults, the pharmacokinetics of ceftriaxone is almost unchanged, the half-life period is slightly prolonged. If the kidney function is impaired, the secretion with bile increases, and if there is a liver pathology, then the excretion of ceftriaxone by the kidneys increases. Patients with renal insufficiency correction of the antibiotic dose is required only when creatinine clearance is less than 10 ml / min.

    Penetration into the spinal cord liquid at Newborns and children with inflammation of the meninges ceftriaxone penetrates into the cerebrospinal fluid, while in the case of bacterial meningitis, the median concentration of the drug in the cerebrospinal fluid is 17% of the concentration of ceftriaxone in the blood serum, which is approximately 4 times greater than with aseptic meningitis. 24 hours after intravenous administration of ceftriaxone in a dose of 50-100 mg / kg body weight, the concentration in the cerebrospinal fluid exceeds 1.4 mg / L.In adults with meningitis, 2 to 25 hours after the administration of ceftriaxone at a dose of 50 mg / kg body weight, the ceftriaxone concentration exceeded the minimum inhibitory concentration for pathogens most frequently causing meningitis.

    Indications:
    Infectious inflammatory diseases caused by susceptible to ceftriaxone pathogens: sepsis, meningitis, disseminated borreliosis Lyme (early and late stages of the disease); infection of the abdominal cavity (peritonitis, inflammatory diseases of the gastrointestinal tract, bile ducts); infection of bones, joints, connective tissue, skin; wound infections; infection in patients with a decreased function of the immune system; infections of the kidneys and urinary tract; respiratory infections, especially pneumonia; as well as infections of the ENT organs, infection of the genital organs, including gonorrhea. Prevention of infections in the postoperative period.
    Contraindications:Hypersensitivity to cephalosporins, penicillins and carbapenems; pregnancy (I trimester).
    Carefully:
    prescribe the drug for renal and / or hepatic insufficiency, ulcerative colitis, enteritis or colitis,associated with the use of antibacterial drugs; Hyperbilirubinemia in newborns, premature infants; during pregnancy (II and III trimester) and during lactation.

    Pregnancy and lactation:Ceftriaxone may be given during pregnancy (II and III trimester) only in cases where the intended benefit to the mother exceeds the possible risk to the fetus. If it is necessary to use ceftriaxone during lactation, the question of stopping breastfeeding should be resolved.
    Dosing and Administration:

    Enter intravenously (IV) or intramuscularly (IM). For adults and for children over 12 years of age:

    The average daily dose is 1000-2000 mg ceftriaxone 1 time per day (every 24 hours).

    In severe cases or in cases of infections caused by moderately sensitive pathogens, a single daily dose can be increased to 4000 mg.

    For infants (including newborns) and children under 12 years of age: when applied once a day, the following scheme is recommended:

    for newborns - 20-50 mg / kg / day (do not exceed the dose of 50 mg / kg / day due to the immature enzyme system in newborns).

    for infants and children under 12: The daily dose is 20-75 mg / kg body weight. Children with a body weight of 50 kg and above should use a dose for adults.A dose of more than 50 mg / kg body weight should be given as an intravenous infusion, for at least 30 minutes.

    Duration of therapy: depends on the course of the disease. Treatment is recommended to continue for another 48 to 72 hours nocjje normalization of temperature and laboratory confirmation of eradication of the pathogen.

    Combination therapy: in studies it has been proven that synergism takes place between ceftriaxone and aminoglycosides in influencing many Gram-negative bacteria. Although it is impossible to predict the potentiated effect of such combinations in advance, in the case of serious and life-threatening infections (for example, Pseudomonas aeruginosa) their joint appointment is justified. In connection with the pharmaceutical incompatibility of ceftriaxone and aminoglycosides, it is necessary to prescribe them separately in recommended doses! Dosing in special cases

    Meningitis: at bacterial meningitis - in children the initial dose is 100 mg / kg of body weight once a day (max. 4000 mg). Once it was possible to isolate the pathogenic microorganism and determine its sensitivity to ceftriaxone, it is necessary to reduce the dose in accordance with the obtained data.The best results were achieved with the following periods of therapy: ________________

    Causative agent

    Duration of therapy

    Neisseria meningitidis

    4 days

    Haemophilus influenzae

    6 days

    Streptococcus pneumoniae

    7 days

    Sensitive Enterobacteriaceae

    10-14 days

    Gonorrhea: for the treatment of gonorrhea caused by both generic and non-penicillinase-resistant strains, the recommended dose is 250 mg once intramuscularly.

    Borrelia Lyme: 50 mg / kg (the highest daily dose is 2000 mg) for adults and children, once a day for 14 days.

    Prevention in the pre- and postoperative period: for the prevention of postoperative infections, a single administration of ceftriaxone in a dose of 1000-2000 mg for 30-90 minutes before surgery is recommended. In operations on the colon and rectum, simultaneous (but separate) administration of 2000 mg of ceftriaxone and one of the antimicrobial agents, which is active against anaerobic microorganisms, is recommended.

    Lack of kidney and liver function: in patients with impaired renal function, under the condition of normal liver function, a dose of ceftriaxone is not necessary to reduce. Only if the kidneys are deficient in the terminal stage (creatinine clearance below 10 ml / min), the daily dose of ceftriaxone should not exceed 2000 mg.

    In patients with impaired hepatic function, if the function of the kidneys is maintained, the dose of ceftriaxone should not be reduced.

    In cases of simultaneous presence of severe pathology of the liver and kidneys, the concentration of ceftriaxone in serum should be monitored regularly. Patients on hemodialysis do not need to enter an additional dose after a dialysis session. It is, however, necessary to monitor the concentration of ceftriaxone in the serum for possible dose adjustment.

    Right-handed solution for intramuscular injection: for intramuscular administration 1000 mg of the drug must be diluted in 3.5 ml of a 1% solution of lidocaine and inserted deep into the gluteus muscle. It is recommended to inject no more than 1000 mg of the drug into one muscle. Trial aspiration helps to avoid unintentional entry into the vessel. The resulting solution can not be administered intravenously!

    Right-hand solution for intravenous administration: for intravenous injection, 1000 mg of the drug must be diluted in 10 ml of water for injection and administered intravenously slowly for 2-4 minutes.

    For intravenous infusion, 2000 mg of the powder should be diluted in approximately 40 ml of the solution,not containing calcium ions, for example, 0.45% or 0.9% sodium chloride solution, 2.5%, 5% or 10% solution of glucose, 5% fructose solution, water for injection.

    The duration of intravenous infusion should be at least 30 minutes. Ceftriaxone solutions should not be mixed or added to solutions containing other antibiotics or other solvents, except for the above, because of potential incompatibility.

    Side effects:

    Allergic reactions: rash, fever or chills, rash, pruritus, rarely - bronchospasm, eosinophilia, erythema multiforme exudative (including Stevens-Johnson syndrome), serum sickness, anaphylactic shock.

    From the digestive system: nausea, vomiting, flatulence, abdominal pain, taste disturbance, stomatitis, glossitis, constipation or diarrhea, pseudomembranous enterocolitis; abnormal liver function (increased activity of "liver" transaminases, less - alkaline phosphatase and bilirubin, cholestatic jaundice), psevdoholelitiaz gallbladder ("sludge''-syndrome), a dysbacteriosis.

    On the part of the organs of hematopoiesis: anemia, leukopenia, leukocytosis, neutropenia, granulocytopenia, lymphopenia,thrombocytopenia, thrombocytopenia, hemolytic anemia, hypocoagulation, decrease in plasma clotting factor concentration (II, VII, IX, X), prolongation of prothrombin time.

    From the urinary system: renal dysfunction (azotemia, increased urea in the blood, hypercreatininaemia, glycosuria, cylindruria, hematuria), oliguria, anuria.

    Local reactions: with iv introduction - phlebitis, soreness along the vein, with the / m introduction - soreness and infiltration at the injection site.

    Other: headache, dizziness, nosebleeds, candidiasis, superinfection.

    Overdose:Excessively high concentrations of ceftriaxone in the plasma can not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. To treat cases of overdose, symptomatic therapy is recommended.
    Interaction:
    Ceftriaxone, suppressing the intestinal flora, interferes with the synthesis of vitamin K. With simultaneous administration with drugs that reduce platelet aggregation (non-steroidal anti-inflammatory drugs, salicylates, sulfinpyrazone), the risk of bleeding increases.With a simultaneous appointment with anticoagulants, the effect of the latter is noted.
    With simultaneous use with "loop" diuretics, for example, furosemide, nephrotoxic action is not observed.
    Ceftriaxone and aminoglycosides have a synergistic effect on many Gram-negative bacteria. Incompatible with ethanol.
    Pharmaceutical interaction. Ceftriaxone should not be mixed or administered concomitantly with other antimicrobials, and should also be added to infusion solutions containing calcium ions.
    Special instructions:
    With concomitant severe renal and hepatic insufficiency, as well as in patients on hemodialysis, the concentration of the drug in plasma should be regularly determined.
    With long-term treatment, it is necessary to regularly monitor the picture of peripheral blood, indicators of the functional state of the liver and kidneys.
    In rare cases, with ultrasound of the gallbladder, darkening is observed, which disappear after the cessation of treatment (even if this phenomenon is accompanied by pain in the right hypochondrium, recommend continued antibiotic prescription and symptomatic treatment).
    During treatment, the use of ethanol is contraindicated - disulfiramoid-like effects are possible (reddening of face, stomach and stomach spasm, nausea, vomiting, headache, lowering of blood pressure, tachycardia, dyspnea).
    Despite the detailed collection of anamnesis, which is the rule for other cephalosporin antibiotics, one can not exclude the possibility of developing an anaphylactic shock that requires immediate therapy - first intravenously epinephrine, then glucocorticosteroids.
    In vitro studies have shown that, like other cephalosporin antibiotics, ceftriaxone is able to displace bilirubin, associated with serum albumin, therefore, in newborns with hyperbilirubinemia, the use of the drug requires extreme caution.
    With prolonged use, vitamin K may be required. It is recommended that only freshly prepared solutions be used.

    Form release / dosage:Powder for the preparation of solution for intravenous and intramuscular injection of 1000 mg.
    Packaging:Powder for the preparation of a solution for intravenous and intramuscular injection of 1000 mg in colorless glass bottles, sealed with rubber stoppers, crimped with aluminum caps.Each bottle, together with instructions for use, is placed in a cardboard box.
    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N014003 / 01
    Date of registration:19.09.2008
    The owner of the registration certificate:Protek Biosystems Pvt. Ltd.Protek Biosystems Pvt. Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspProtekh Biosystems Pvt.LtdProtekh Biosystems Pvt.LtdRussia
    Information update date: & nbsp22.11.2015
    Illustrated instructions
      Instructions
      Up